



Atty. Dkt. No. 080382-0108

2161

#4
BT
12.04-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Royce Morrison
Title: PROCESS FOR CONSUMER-DIRECTED PRESCRIPTION INFLUENCE AND HEALTH CARE PROFESSIONAL INFORMATION
Appl. No.: 09/899,526
Filing Date: July 6, 2001
Examiner: Unassigned
Art Unit: 2161

RECEIVED
OCT 30 2001
Technology Center 2100

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 C.F.R. §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

This Information Disclosure Statement is being provided in compliance with 37 C.F.R. 1.97(b), prior to the mailing date of the first official action. Consequently, no fee is required in connection with its filing.



Atty. Dkt. No. 080382-0108

Applicant respectfully requests that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: October 29, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

By

Mary Michelle Kile

Mary Michelle Kile
Attorney for Applicant
Registration No. 35,217

RECEIVED
OCT 30 2001
Technology Center 2100

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 080382-0108	SERIAL NO. 09/899,526
INFORMATION DISCLOSURE CITATION October 29, 2001 <i>(Use several sheets if necessary)</i>		APPLICANT Royce Morrison	
		FILING DATE 07/06/01	GROUP ART UNIT 2161

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,862,223	01/19/1999	Walker et al.			
	A2	5,867,821	02/02/1999	Ballantyne et al.			
	A3	6,014,629	01/11/2000	DeBruin-Ashton			
	A4	5,964,700	10/12/1999	Tallman et al.			
	A5	6,012,035	01/04/2000	Freeman Jr. et al.			
	A6	5,983,220	11/09/1999	Schmitt			
	A7	6,018,742	01/25/2000	Herbert III			

FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	A8	0 957 201	05/13/1998	EPO				
	A9	WO 00/39737	07/06/2000	WIPO				

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>	
	A10 Drug Approvals Part 1 (A-C), 9 pp., http://www.fda.gov/cder/approval/main.htm (printed November 2000).
	A11 Hradecky, G., "Biotechnology: 21 st century medicine, Biotech expands its role in the world of medical innovation," <u>Pharmaceutical Representative</u> , pp. 18-19, January 2000.
	A12 Sackett, D. L. <i>et al.</i> , <u>Evidence-based Medicine, How to Practice and Teach EBM</u> , pp. 1-20., Churchill Livingstone, ed., 1997.
	A13 Gabe, L. <i>et al.</i> , "Breaking through the access barrier," <u>Pharmaceutical Representative</u> , p 23., October 1999.
	A14 "Report addresses physician access," <u>Pharmaceutical Representative</u> , p.13, February 2000.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 080382-0108		SERIAL NO. 09/899,526	
INFORMATION DISCLOSURE CITATION October 29, 2001 (Use several sheets if necessary)				APPLICANT Royce Morrison			
				FILING DATE 07/06/01		GROUP ART UNIT 2161	
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)							
	A15	Page, L., "More clinics ban drug samples, citing cost, safety concerns," <u>American Medical News</u> , 4 pp, October 16, 2000.					
	A16	"Headache treatments lag behind," <u>Pharmaceutical Representative</u> , p. 16, May 2000.					
	A17	Elliott, V. S., "Hypertension remains poorly controlled," <u>American Medical News</u> , 2 pp., September 11, 2000.					
	A18	Weber, J. et al., "The New Era of Lifestyle Drugs," <u>Business Week</u> , pp. 92-98, May 11, 1998.					
	A19	Stevens, L., "Information at the point of patient contact," <u>Medicine on the Net</u> , pp. 5-6, June 2000, http://www.corhealth.com .					
	A20	Foubister, V., "Physicians rarely give patients enough information," <u>American Medical News</u> , p. 15, January 17, 2000.					
	A21	"DTC ads 'have created Rx awareness levels similar to those of OT brands,'" <u>Marketletter via news Edge Corporation</u> , pp. 1-4, March 22, 1999.					
	A22	Promotional Material from Novartis Pharmaceuticals Corporation regarding Lamisil®, 5 pp., 1998.					
	A23	Kolata, G., "Pharmacists Help Drug Promotions," <u>The New York Times</u> , pp. A1, D2, July 29, 1994.					
	A24	O'Harrow, R., "Plans' Access To Pharmacy Data Raises Privacy Issue," <u>The Washington Post</u> , pp. A1, A26, A27, September 27, 1998.					
	A25	O'Harrow, R., "Between Doctor and Patient, a Three-Way Relationship," <u>The Washington Post</u> , p. A26, September 27, 1998.					
	A26	Hilzenrath, D., "Drug Firms Said to Pressure Doctors," <u>The Washington Post</u> , p. E3, August 14, 1997.					
	A27	McCarthy, R., "Linking Physicians, Pharmacists, and PBMs Electronically," <u>Drug Benefit Trends</u> , Vol. 9(10), pp. 36-39, October 1997.					
	A28	Pomerantz, J., "A Case of Inappropriate Use of Patient Pharmacy Data," <u>Drug Benefit Trends</u> , Vol. 12(1), pp. 2,6, January 2000.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 080382-0108	SERIAL NO. 09/899,526
INFORMATION DISCLOSURE CITATION October 29, 2001 (Use several sheets if necessary)				APPLICANT Royce Morrison	
				FILING DATE 07/06/01	GROUP ART UNIT 2161
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	A29	Lo B. et al, "uses and Abuses of Prescription Drug Information in Pharmacy Benefits Management Programs," <u>Journal of American Medical Association</u> , Vol. 283, pp. 801-806, 2000.			
	A30	Rosoff, A., "The Changing Face of Pharmacy Benefits Management: Information Technology Pursues a Grand Mission," <u>Saint Louis University Law Journal</u> , Vol. 42(1), pp. 1-53, 1998.			
	A31	L. Caba, "A Life-Saving Preceptorship," <u>Pharmaceutical Representative</u> , pg. 16, July 1998.			
	A32	Stevens, L., "Evidence-based Medicine: Applying New Rules to Medical Problem Solving," <u>Medicine on the Net</u> , May 1998, http://www.mednet-i.com .			
	A33	Wechsler, J., "A Conversation With FDA Commissioner Jane Henney," <u>Pharmaceutical Executive</u> , pp. 32-36, 38, 40, 42, December 1999.			
	A34	Fleming, M., "Cheers and Concerns For DTC From A Family Physician," <u>MM&M</u> , pp. 74, 76, 78, November 1998.			
	A35	S. G. Stolberg, "Now, Prescribing Just What the Doctor Ordered," <u>New York Times</u> , pg. 3, section 4, August 10, 1997.			
	A36	Mulrow, C., "Systematic Reviews: Critical Links in the Great Chain of Evidence," <u>Annals of Internal Medicine</u> , Vol. 126, No. 5, pp. 389-391, March 1, 1997.			
	A37	"Ensuring Quality Health Care: The Challenge of Measuring Performance and Consumer Satisfaction - Workshop Summary," Agency for Health Care Policy and Research, 4-6 June 1997.			
EXAMINER			DATE CONSIDERED		
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.					

RECEIVED
 OCT 30 2001
 Technology Center 2100